XLO News

The fall IPO market kept a brisk pace this past week with 11 IPOs, led by restaurant chain Portillo’s (PTLO). SPACs also stayed active, with 18 blank check IPOs. There was one postponement: winery Winc (WBEV). New filers continue to flood the pipeline, with 14 IPOs and X SPACs submitting initial filings. Portillo’s (PTLO) priced...read more

Xilio Therapeutics, a Phase 1 biotech developing novel molecules to treat solid tumors, raised $118 million by offering 7.4 million shares at $16, the low end of the range of $16 to $18. Xilio has built its geographically precise solutions (GPS) platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic...read more

Xilio Therapeutics, a Phase 1 biotech developing novel molecules to treat solid tumors, announced terms for its IPO on Monday. The Waltham, MA-based company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Xilio Therapeutics would command a fully diluted market value of $487 million. Xilio has built...read more

The IPO market remained active this past week as four IPOs raised $2.3 billion, joined by two direct listings. SPAC activity kept steady with nine blank check IPOs. New filers continue to pour into the IPO pipeline, with 17 IPOs and 10 SPACs submitting initial filings. NYSE direct listing Warby Parker (WRBY) opened for trading at $54 (+35% vs. reference price)...read more